Potentiated cytotoxic effects of statins and ajoene in murine melanoma cells

Melanoma Research

Volumn 19, Issue 2, 2009, Pages 69-74

  Ledezma, Eliades ^a   Wittig, Olga ^b   Alonso, Jose ^b   Cardier, Jose E ^b  

^a Fundacite   (Venezuela)

^b INSTITUTO VENEZOLANO DE INVESTIGACIONES CIENTÍFICAS   (Venezuela)

Author keywords

[No Author keywords available]

Indexed keywords

AJOENE; ATORVASTATIN; GERANYLGERANYL PYROPHOSPHATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; PRAVASTATIN; DISULFIDE; HEPTANOIC ACID DERIVATIVE; ISOPRENOID PHOSPHATE; PYRROLE DERIVATIVE; TERPENE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; HYPOTHESIS; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; ANIMAL; APOPTOSIS; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; MELANOCYTE; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DISULFIDES; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; FLOW CYTOMETRY; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MELANOCYTES; MELANOMA, EXPERIMENTAL; MEVALONIC ACID; MICE; POLYISOPRENYL PHOSPHATES; PRAVASTATIN; PYRROLES; TERPENES;

EID: 65449119977     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32831bc45a     Document Type: Article

References (45)

1. Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM. Statins and cancer prevention. Nat Rev Cancer 2005; 5:930-942.
2. Graaf RM, Richel DJ, Van Noorden C, Guchelaar H. Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer. Cancer Treat Rev 2004; 30:609-641.
3. Kato K, Cox AD, Hisaka MM, Graham SM, Buss JE, Der CJ. Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity. Proc Natl Acad Sci U S A 1992; 89:6403-6407.
4. Gelb MH. Protein prenylation, et cetera - signal transduction in two dimensions. Science 1997; 275:1750-1751.
5. Rebollo A, Martinez A. Ras proteins: recent advances and new functions. Blood 1999; 94:2971-2980.
6. Reuter CW, Morgan MA, Bergmann L. Targeting the Ras signaling pathway: a rational, mechanism-based treatment for hematologic malignancies? Blood 2000; 96:1655-1669.
7. Magee T, Marshall C. New insights into the interaction of Ras with the plasma membrane. Cell 1999; 98:9-12.
8. Van de Donk NW, Kamphuis MM, van Kessel B, Lokhorst HM, Bloem AC. Inhibition of protein geranylgeranylation induces apoptosis in myeloma plasma cells by reducing Mcl-1 protein levels. Blood 2003; 102:3354-3362.
9. Dai Y, Khanna P, Chen S, Pei XY, Dent P, Grant S. Statins synergistically potentiate 7-hydroxystaurosporine (UCN-01) lethality in human leukemia and myeloma cells by disrupting Ras farnesylation and activation. Blood 2007; 109:4415-4423.
10. Elson CE, Peffle DM, Hentosh P, Mo H. Isoprenoid-mediated inhibition of mevalonate synthesis: potential application to cancer. Proc Soc Exp Biol Med 1999; 221:294-311.
11. Maron DJ, Fazio S, Linto M. Current perspectives on statins. Circulation 2000; 101:207-213.
12. Vaughan CJ, Gotto AM, Basson CT. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol 2000; 35:1-10.
13. Farwell WR, Scranton RE, Lawler EV, Lew RA, Brophy MT, Fiore LD, Gaziano JM. The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst 2008; 100:134-139.
14. Xia Z, Tan MM, Wong WW, Dimitroulakos J, Minden MD, Penn LZ. Blocking protein geranylgeranylation is essential for lovastatin induced apoptosis of human acute myeloid leukemia cells. Leukemia 2001; 15:1398-1407.
15. Jakobisiak M, Golab J. Potential antitumor effects of statins. Int J Oncol 2003; 23:1055-1069.
16. Shellman YG, Ribble D, Miller L, Gendall J, Vanbuskirk K, Kelly D, et al. Lovastatin-induced apoptosis in human melanoma cell lines. Melanoma Res 2005; 15:83-89.
17. Collison EA, Kleer C, Wu M. Atorvastatin prevents Rho C isoprenylation, invasion and metastasis in human melanoma cells. Mol Cancer Ther 2003; 2 :941-948.
18. Freeman SR, Drake AL, Heilig LF, Graber M, McNealy K, Schilling LM, et al. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. J Natl Cancer Inst 2006; 98:1538-1546.
19. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007; 120:833-843.
20. Koomen ER, Joosse A, Herings RM, Casparie MK, Bergman W, Nijsten T, et al. Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin? Eur J Cancer 2007; 43:2580-2589.
21. Sassano A, Platanias LC. Statins in tumor suppression. Cancer Lett 2008; 260:11-19.
22. Dorant E, van-den-Brandt PA, Goldbohm RA, Hermus RJ, Sturmans F. Garlic and its significance for prevention of cancer in humans: a critical review. Br J Cancer 1993; 67:424-429.
23. Takeyama H, Hoon DS, Saxton RE, Morton DL, Irie RF. Growth inhibition and modulation of cell markers of melanoma by S-allyl cysteine. Oncology 1993; 50 :63-69.
24. Singh SV, Mohan RR, Agarwal R, Benson PJ, Hu X, Rudy MA, et al. Novel anti-carcinogenic activity of an organosulfide from garlic: inhibition of H-ras oncogene transformed tumor growth in vivo by diallyl disulfide is associated with inhibition of p21H-ras processing. Biochem Biophys Res Commun 1996; 225:660-665.
25. Ledezma E, Apitz R, Cardier J. Apoptotic and anti-adhesion effect of ajoene, a garlic derived compound, on the murine melanoma B16F10 cells: possible role of caspase-3 and the a4b1 integrin. Cancer Lett 2004; 206:35-41.
26. Hassan HT. Ajoene (natural garlic compound): a new anti-leukaemia agent for AML therapy. Leuk Res 2004; 28:667-671.
27. Shafemberg K, Wagner R, Wagner GK. The cytotoxic effect of ajoene, a natural product from garlic, investigated with different cell lines. Cancer Lett 1990; 53:103-108.
28. Nishikawa T, Yamada N, Hattori A, Fukuda H, Fujino T. Inhibition by ajoene of skin-tumor promotion in mice. Biosci Biotechnol Biochem 2002; 66:2221-2223.
29. Dirsch VM, Antisperger DS, Hentze H, Vollmar AM. Ajoene an experimental anti-leukemic drug: mechanism of cell death. Leukemia 2002; 16:74-83.
30. Li M, Ciu J, Ye Y, Min JM, Zhang LH, Wang K, et al. Antitumor activity of Z-ajoene a natural compound purified from garlic antimitotic and microtubule-interaction properties. Carcinogenesis 2002; 23:573-579.
31. Tadi PP, Teel RW, Lau BH. Organosulfur compounds of garlic modulate mutagenesis, metabolism, and DNA binding of aflotoxin B1. Nutr Cancer 1991; 15:87-95.
32. Tilli CM, Stavast-Kooy AJ, Vuerstaek JD, Thissen MR, Krekels GA, Ramaekers FC, et al. The garlic derived organosulfur component ajoene decreases basal cell carcinoma tumour size by inducing apoptosis. Arch Dermatol Res 2003; 295:117.
33. Ledezma E, De Sousa L, Jorquera A, Sanchez J, Lander A, Rodríguez E, et al. The effect of topical ajoene, an organosulphur derived from garlic, in non-melanomic skin cancer. Acta Cientifica Venezolana 1996; 47:137.
34. Gebhardt R, Beck H, Wagner KG. Inhibition of cholesterol biosynthesis by allicin and ajoene in rat hepatocytes and HepG2 cells. Biochim Biophis Acta 1994; 1213:57-62.
35. Ferri N, Yokoyama K, Sadilek M, Paoletti R, Apitz-castro R, Gelb M, et al. Ajoene, a garlic compound, inhibits protein prenylation and arterial smooth muscle cell proliferation. Br J Pharmacol 2003; 138:811-818.
36. Apitz-Castro R, Ledezma E, Escalante J, Jain MK. The molecular basis of the antiplatelet action of ajoene: direct interaction with the fibrinogen receptor. Biochem Biophys Res Commun 1986; 141:145-150.
37. Glynn SA, O'Sullivan D, Eustace AJ, Clynes M, O'Donovan N. The 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, simvastatin, lovastatin and mevastatin inhibit proliferation and invasion of melanoma cells. BMC Cancer 2008; 8:9.
38. Mo H, Elson CE. Studies of the isoprenoid-mediated inhibition of mevalonate synthesis applied to cancer chemotherapy and chemoprevention. Exp Biol Med 2004; 229:567-585.
39. Kaneta S, Satoh K, Kano S, Kanda M, Ichihara K. All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. Atherosclerosis 2003; 170:237-243.
40. Debouzy JC, Neumann JM, Herve M, Daveloose D, Viret J, Apitz-Castro JR. Interaction of antiaggregant molecule ajoene with membranes. An ESR and 1H, 2H, 31P-NMR study. Eur Biophys J 1989; 17:211-216.
41. McAnally JA, Gupta J, Sodhani S, Bravo L, Mo H. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo. Exp Biol Med 2007; 232:523-531.
42. Ahmed N, Laverick L, Sammons J, Zhang H, Maslin DJ, Hassan HT. Ajoene a garlic-derived natural compound, enhances chemotherapy-induced apoptosis in human myeloid leukaemia CD-34 positive CD7 negative resistant cells. Anticancer Res 2001; 21:3519-3523.
43. Apitz-Castro R, Escalante J, Vargas R, Jain MK. Ajoene, the antiplatelet principle of garlic, synergistically potentiates the antiaggregatory action of prostacyclin, forskolin, indomethacin acid, dipiridamol on human platelets. Thromb Res 1986; 42:303-311.
44. Feleszko W, Meynarczuk I, Olszewska D, Jalili A, Grzela T, Lasek W, et al. Lovastatin potentiates antitumor activity of doxorubicin in murine melanoma via an apoptosis-dependent mechanism. Int J Cancer 2002; 100:111-118.
45. Feleszko W, Zagozdzon R, Golab J, Jakobisiak M. Potentiated antitumour effects of cisplatin and lovastatin against MmB16 melanoma in mice. Eur J Cancer 1998; 34:406-411.